Monitoring of KRAS -mutated ctDNA to discriminate pseudo-progression from true progression during anti-PD-1 treatment of lung adenocarcinoma - Guibert, Nicolas; Mazieres, Julien; Delaunay, Myriam; Casanova, Anne; Farella, Magali; Keller, Laura; Favre, Gilles; Pradines, Anne (Oncotarget, 2017)
Keywords: Adenocarcinoma - drug therapy; Adenocarcinoma - pathology; Adenocarcinoma of Lung; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Case Report; Circulating Tumor DNA - genetics; Disease Progression; Humans; Immunotherapy - methods; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; KRAS mutation; anti-PD-1; immunotherapy; circulating tumor DNA; non-small-cell lung cancer